• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

流感 B 型神经氨酸酶中的 H134 和 430 环区域的替换可以导致对多种神经氨酸酶抑制剂的敏感性降低。

Substitutions at H134 and in the 430-loop region in influenza B neuraminidases can confer reduced susceptibility to multiple neuraminidase inhibitors.

机构信息

CSIRO Australian Centre for Disease Preparedness, 5 Portarlington Rd., East Geelong, 3219, Australia.

CSIRO Manufacturing, 343 Royal Parade, Parkville, 3052, Australia.

出版信息

Antiviral Res. 2020 Oct;182:104895. doi: 10.1016/j.antiviral.2020.104895. Epub 2020 Aug 1.

DOI:10.1016/j.antiviral.2020.104895
PMID:32750469
Abstract

With the introduction of the influenza specific neuraminidase inhibitors (NAIs) in 1999, there were concerns about the emergence and spread of resistant viruses in the community setting. Surveillance and testing of community isolates for their susceptibility to the NAIs was initially carried out by the Neuraminidase Inhibitor Susceptibility Network (NISN) and has subsequently been taken on by the global WHO influenza network laboratories. During the NISN surveillance, we identified two Yamagata lineage influenza B viruses with amino acid substitutions of H134Y (B/Auckland/2/2001) or W438R (B/Yokohama/12/2005) which had slightly elevated IC values for zanamivir and/or oseltamivir, but not sufficiently to be characterized as mild outliers at the time. As it has now been well demonstrated that mixed populations can mask the true magnitude of resistance of a mutant, we re-examined both of these isolates by plaque purification to see if the true susceptibilities were being masked due to mixed populations. Results confirmed that the B/Auckland isolate contained both wild type and H134Y mutant populations, with mutant IC values > 250 nM for both oseltamivir and peramivir in the enzyme inhibition assay. The B/Yokohama isolate also contained both wild type and W438R mutant populations, the latter now demonstrating IC values > 400 nM for zanamivir, oseltamivir and peramivir. In addition, plaque purification of the B/Yokohama isolate identified viruses with other single neuraminidase substitutions H134Y, H134R, H431R, or T436P. H134R and H431R viruses had IC values > 400 nM and >250 nM respectively against all three NAIs. All changes conferred much greater resistance to peramivir than to zanamivir, and less to oseltamivir, and affected the kinetics of binding and dissociation of the NAIs. Most affected affinity (K) for the MUNANA substrate, but some had decreased while others had increased affinity. Despite resistance in the enzyme assay, no reduced susceptibility was seen in plaque reduction assays in MDCK cells for any of the mutant viruses. None of these substitutions was in the active site. Modelling suggests that these substitutions affect the 150 and 430-loop regions described for influenza A NAs, suggesting they may also be important for substrate and inhibitor binding for influenza B NAs.

摘要

随着 1999 年流感特异性神经氨酸酶抑制剂(NAI)的引入,人们担心社区环境中耐药病毒的出现和传播。最初,社区分离株对 NAI 的敏感性由神经氨酸酶抑制剂敏感性网络(NISN)进行监测和检测,随后由全球世卫组织流感网络实验室承担。在 NISN 监测期间,我们发现了两株带有 H134Y(B/Auckland/2/2001)或 W438R(B/Yokohama/12/2005)氨基酸取代的 Yamagata 谱系流感 B 病毒,它们对扎那米韦和/或奥司他韦的 IC 值略有升高,但不足以在当时被认为是温和的异常值。由于现在已经充分证明,混合种群可以掩盖突变体耐药的真实程度,因此我们通过斑块纯化重新检查了这两种分离株,以确定是否由于混合种群而掩盖了真实的敏感性。结果证实,B/Auckland 分离株既包含野生型,也包含 H134Y 突变型,在酶抑制测定中,奥司他韦和帕拉米韦的突变体 IC 值均>250 nM。B/Yokohama 分离株也包含野生型和 W438R 突变型,后者现在对扎那米韦、奥司他韦和帕拉米韦的 IC 值>400 nM。此外,B/Yokohama 分离株的斑块纯化鉴定出具有其他单个神经氨酸酶取代 H134Y、H134R、H431R 或 T436P 的病毒。H134R 和 H431R 病毒对所有三种 NAI 的 IC 值均>400 nM 和>250 nM。所有这些变化都使对帕拉米韦的耐药性大大增加,而对扎那米韦的耐药性则较低,对奥司他韦的耐药性也较低,并且影响了 NAI 的结合和解离动力学。大多数影响对 MUNANA 底物的亲和力(K),但有些降低,而有些增加。尽管在酶测定中存在耐药性,但在 MDCK 细胞中的斑块减少测定中,没有观察到任何突变病毒的敏感性降低。这些取代均不在活性部位。建模表明,这些取代影响了描述流感 A NAs 的 150 和 430 环区,表明它们对流感 B NAs 的底物和抑制剂结合也可能很重要。

相似文献

1
Substitutions at H134 and in the 430-loop region in influenza B neuraminidases can confer reduced susceptibility to multiple neuraminidase inhibitors.流感 B 型神经氨酸酶中的 H134 和 430 环区域的替换可以导致对多种神经氨酸酶抑制剂的敏感性降低。
Antiviral Res. 2020 Oct;182:104895. doi: 10.1016/j.antiviral.2020.104895. Epub 2020 Aug 1.
2
Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2015-2016.全球 2015-2016 年人类流感病毒对神经氨酸酶抑制剂的敏感性更新。
Antiviral Res. 2017 Oct;146:12-20. doi: 10.1016/j.antiviral.2017.08.004. Epub 2017 Aug 10.
3
Mutations at the monomer-monomer interface away from the active site of influenza B virus neuraminidase reduces susceptibility to neuraminidase inhibitor drugs.流感 B 病毒神经氨酸酶单体-单体界面远离活性部位的突变降低了对神经氨酸酶抑制剂药物的敏感性。
J Infect Chemother. 2013 Oct;19(5):891-5. doi: 10.1007/s10156-013-0589-6. Epub 2013 Mar 26.
4
Neuraminidase inhibitor susceptibility surveillance of influenza viruses circulating worldwide during the 2011 Southern Hemisphere season.2011 年南半球流感季节期间全球流行的流感病毒神经氨酸酶抑制剂敏感性监测。
Influenza Other Respir Viruses. 2013 Sep;7(5):645-58. doi: 10.1111/irv.12113. Epub 2013 Apr 10.
5
Neuraminidase inhibitor susceptibility profile of pandemic and seasonal influenza viruses during the 2009-2010 and 2010-2011 influenza seasons in Japan.2009-2010 年和 2010-2011 年流感季节日本大流行和季节性流感病毒的神经氨酸酶抑制剂敏感性特征。
Antiviral Res. 2013 Sep;99(3):261-9. doi: 10.1016/j.antiviral.2013.06.003. Epub 2013 Jun 17.
6
A single E105K mutation far from the active site of influenza B virus neuraminidase contributes to reduced susceptibility to multiple neuraminidase-inhibitor drugs.单个远离流感 B 病毒神经氨酸酶活性部位的 E105K 突变有助于降低对多种神经氨酸酶抑制剂药物的敏感性。
Biochem Biophys Res Commun. 2012 Dec 7;429(1-2):51-6. doi: 10.1016/j.bbrc.2012.10.095. Epub 2012 Nov 3.
7
Screening for Neuraminidase Inhibitor Resistance Markers among Avian Influenza Viruses of the N4, N5, N6, and N8 Neuraminidase Subtypes.对N4、N5、N6和N8神经氨酸酶亚型禽流感病毒中的神经氨酸酶抑制剂耐药性标志物进行筛查。
J Virol. 2017 Dec 14;92(1). doi: 10.1128/JVI.01580-17. Print 2018 Jan 1.
8
Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2013-2014.2013 - 2014年全球人类流感病毒对神经氨酸酶抑制剂敏感性的最新情况
Antiviral Res. 2015 May;117:27-38. doi: 10.1016/j.antiviral.2015.02.003. Epub 2015 Feb 23.
9
Characterization of influenza B viruses with reduced susceptibility to influenza neuraminidase inhibitors.对流感神经氨酸酶抑制剂敏感性降低的乙型流感病毒的特征分析
Antiviral Res. 2022 Apr;200:105280. doi: 10.1016/j.antiviral.2022.105280. Epub 2022 Mar 15.
10
Peramivir susceptibilities of recombinant influenza A and B variants selected with various neuraminidase inhibitors.用各种神经氨酸酶抑制剂筛选出的重组甲型和乙型流感病毒变体对帕拉米韦的敏感性
Antivir Ther. 2017;22(8):711-716. doi: 10.3851/IMP3158.

引用本文的文献

1
Influenza neuraminidase mutations and resistance to neuraminidase inhibitors.流感神经氨酸酶突变与对神经氨酸酶抑制剂的耐药性。
Emerg Microbes Infect. 2024 Dec;13(1):2429627. doi: 10.1080/22221751.2024.2429627. Epub 2024 Nov 26.